Drugs / BG-C0902
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07181681 | Nov 2025 → Nov 2027 expected | cancer | BeOne Medicines | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BG-C0902 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07181681 ↗ |
| Modality | Monoclonal antibody | “a fully humanized anti-epidermal growth factor receptor (EGFR) and anti-mesenchymal-epithelial transition (MET) antibody” NCT07181681 ↗ |
| Route | Intravenous | “Administered by intravenous infusion” NCT07181681 ↗ |
| Target | EGFR | “anti-epidermal growth factor receptor (EGFR)” NCT07181681 ↗ |
| Target | MET | “anti-mesenchymal-epithelial transition (MET)” NCT07181681 ↗ |